CIS Pharma

Executive Summary

CIS Pharma is a Swiss private life science company founded in 1998, dedicated to improving patient outcomes in ophthalmology and oncology. The company combines expertise in antibody development, drug delivery, and biomaterials to create novel molecules and cutting-edge medical devices that enhance the risk-benefit profile of existing treatments. With a focus on healthier eyes and better cancer therapies, CIS Pharma leverages its R&D capabilities to address significant unmet medical needs. Despite its long history, the company operates with limited public disclosure, typical of private entities, which restricts visibility into financials and pipeline specifics. However, its dual therapeutic focus and in-house innovation suggest a differentiated approach in niche markets. The company’s Swiss base adds credibility, given the region’s strong life sciences ecosystem. Overall, CIS Pharma appears well-positioned in its chosen fields, though the lack of transparent milestones tempers conviction.

Upcoming Catalysts (preview)

• TBDOphthalmic drug delivery platform update60% success
• TBDOncology pipeline advancement50% success